{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:57:25Z","timestamp":1793055445334,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13318-016-0391-9","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T06:14:22Z","timestamp":1482560062000},"page":"767-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model"],"prefix":"10.1007","volume":"42","author":[{"given":"Ebtehal","family":"El-Demerdash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaia A.","family":"Abdel-Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam M.","family":"El-Bakly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"key":"391_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bpg.2011.02.009","volume":"25","author":"M Pinzani","year":"2011","unstructured":"Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:281\u201390.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"391_CR2","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.3748\/wjg.v12.i41.6639","volume":"12","author":"F Moal","year":"2006","unstructured":"Moal F, Veal N, Vuillemin E, Barriere E, Wang J, Fizanne L, et al. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO\/NO in bile duct ligated rats. World J Gastroenterol. 2006;12:6639\u201345.","journal-title":"World J Gastroenterol"},{"key":"391_CR3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0016-5085(00)70379-9","volume":"118","author":"DC Rockey","year":"2000","unstructured":"Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000;118:1261\u20135.","journal-title":"Gastroenterology"},{"key":"391_CR4","first-page":"325","volume":"97","author":"W Laleman","year":"2006","unstructured":"Laleman W, Nevens F. Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding. Minerva Med. 2006;97:325\u201345.","journal-title":"Minerva Med"},{"key":"391_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/MEG.0b013e3283367a99","volume":"22","author":"D Tripathi","year":"2010","unstructured":"Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010;22:905\u201311.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"391_CR6","doi-asserted-by":"crossref","first-page":"e010902","DOI":"10.1136\/bmjopen-2015-010902","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6(5):e010902.","journal-title":"BMJ Open"},{"key":"391_CR7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.taap.2012.04.012","volume":"261","author":"N Hamdy","year":"2012","unstructured":"Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol. 2012;261:292\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"key":"391_CR8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1530-0277.2012.01773.x","volume":"36","author":"J Liu","year":"2012","unstructured":"Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res. 2012;36:1587\u201399.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"391_CR9","doi-asserted-by":"crossref","first-page":"e0148868","DOI":"10.1371\/journal.pone.0148868","volume":"11","author":"RF Araujo Junior","year":"2016","unstructured":"Araujo Junior RF, Garcia VB, Leitao RF, Brito GA, Miguel Ede C, Guedes PM, Araujo AA. Carvedilol improves inflammatory response, oxidative stress and fibrosis, in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 2016;11(2):e0148868.","journal-title":"PLoS One"},{"key":"391_CR10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","volume":"26","author":"T Morgan","year":"1994","unstructured":"Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335\u201346.","journal-title":"Clin Pharmacokinet"},{"key":"391_CR11","first-page":"958","volume":"26","author":"WH Schaefer","year":"1998","unstructured":"Schaefer WH, Politowski J, Hwang B, Dixon F Jr, Goalwin A, Gutzait L, et al. Metabolism of carvedilol in dogs, rats, and mice. Drug Metab Dispos. 1998;26:958\u201369.","journal-title":"Drug Metab Dispos"},{"key":"391_CR12","first-page":"814","volume":"53","author":"OE Brodde","year":"2003","unstructured":"Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53:814\u201322.","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 1","key":"391_CR13","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1097\/00005344-199219001-00028","volume":"19","author":"G Neugebauer","year":"1992","unstructured":"Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S142\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"391_CR14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2165\/00003088-200746120-00002","volume":"46","author":"U Klotz","year":"2007","unstructured":"Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46:985\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"391_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bpg.2011.02.004","volume":"25","author":"P Starkel","year":"2011","unstructured":"Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol. 2011;25:319\u201333.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"391_CR16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/hc0802.104503","volume":"105","author":"H Yaoita","year":"2002","unstructured":"Yaoita H, Sakabe A, Maehara K, Maruyama Y. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 2002;105:975\u201380.","journal-title":"Circulation"},{"key":"391_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","volume":"28","author":"S Reitman","year":"1957","unstructured":"Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28:56\u201363.","journal-title":"Am J Clin Pathol"},{"key":"391_CR18","first-page":"894","volume":"42","author":"N Bayraktar","year":"2012","unstructured":"Bayraktar N, Devay SD, Taslipinar MY, Omeroglu S, Gumuslu S, Kavutcum M, Canbolat O. The effects of stobadine on purine metabolism in rats treated with carbon tetrachloride. Turk J Med Sci. 2012;42:894\u2013900.","journal-title":"Turk J Med Sci."},{"key":"391_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0003-9861(61)90291-0","volume":"93","author":"JF Woessner Jr","year":"1961","unstructured":"Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440\u20137.","journal-title":"Arch Biochem Biophys"},{"key":"391_CR20","doi-asserted-by":"crossref","unstructured":"Abdel Fattah LE, Mohamed TA, Taha EA. Spectrofluorimetric determination of carvedilol in dosage form and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride. CI CEQ 2010;16:31\u20138.","DOI":"10.2298\/CICEQ090623006E"},{"key":"391_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/hepr.12143","volume":"44","author":"A Hakucho","year":"2014","unstructured":"Hakucho A, Liu J, Liu X, Fujimiya T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res. 2014;44:560\u201370.","journal-title":"Hepatol Res."},{"key":"391_CR22","doi-asserted-by":"crossref","first-page":"e69276","DOI":"10.1371\/journal.pone.0069276","volume":"8","author":"RM Breikaa","year":"2013","unstructured":"Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Multimechanistic antifibrotic effect of biochanin a in rats: implications of proinflammatory and profibrogenic mediators. PLoS One. 2013;8:e69276.","journal-title":"PLoS One"},{"key":"391_CR23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2010.11.035","volume":"55","author":"Y Liu","year":"2011","unstructured":"Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, et al. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011;55:612\u201325.","journal-title":"J Hepatol"},{"key":"391_CR24","volume-title":"Lehninger: principles of biochemistry","author":"DL Nelson","year":"2004","unstructured":"Nelson DL, Cox MM. The three-dimensional structure of proteins. In: Lehninger AL, editor. Lehninger: principles of biochemistry. 4th ed. New York: Freeman WH; 2004.","edition":"4"},{"key":"391_CR25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/0975-1483.104366","volume":"4","author":"Z Mahmud","year":"2012","unstructured":"Mahmud Z, Bachar S, Qais N. Antioxidant and hepatoprotective activities of ethanolic extracts of leaves of premna esculenta Roxb. against carbon tetrachloride-induced liver damage in rats. J Young Pharm. 2012;4:228\u201334.","journal-title":"J Young Pharm"},{"key":"391_CR26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1386-6346(99)00068-6","volume":"17","author":"TC Peterson","year":"2000","unstructured":"Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ. Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared to AHR knockout mice. Hepatol Res. 2000;17:112\u201325.","journal-title":"Hepatol Res."},{"key":"391_CR27","first-page":"119","volume":"56","author":"ZS Ibrahim","year":"2008","unstructured":"Ibrahim ZS, Ishizuka M, Soliman M, ElBohi K, Sobhy W, Muzandu K, et al. Protection by Nigella sativa against carbon tetrachloride-induced downregulation of hepatic cytochrome P450 isozymes in rats. Jpn J Vet Res. 2008;56:119\u201328.","journal-title":"Jpn J Vet Res"},{"key":"391_CR28","first-page":"361","volume":"1","author":"KV Chin","year":"1990","unstructured":"Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990;1:361\u20135.","journal-title":"Cell Growth Differ"},{"key":"391_CR29","first-page":"R927","volume":"270","author":"P Wang","year":"1996","unstructured":"Wang P, Chaudry IH. Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Am J Physiol. 1996;270:R927\u201338.","journal-title":"Am J Physiol"},{"key":"391_CR30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-230X-12-168","volume":"12","author":"YL Yang","year":"2012","unstructured":"Yang YL, Di L, Duan YY, Liu X, Liu J, Yang RJ, et al. A prospective experimental study of liver fibrosis with ultrasound and its correlation with hepatic reserve function and hemodynamics. BMC Gastroenterol. 2012;12:168.","journal-title":"BMC Gastroenterol."},{"key":"391_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","volume":"30","author":"R Banares","year":"1999","unstructured":"Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79\u201383.","journal-title":"Hepatology"},{"key":"391_CR32","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/j.1572-0241.2004.40179.x","volume":"99","author":"HC Lin","year":"2004","unstructured":"Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol. 2004;99:1953\u20138.","journal-title":"Am J Gastroenterol"},{"key":"391_CR33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147\u201361.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-016-0391-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T02:59:46Z","timestamp":1505271586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-016-0391-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s13318-016-0391-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,23]]}}}